April 4, 2018 / 12:08 PM / 22 days ago

BRIEF-Tenax Therapeutics Announces Results Of Pre-Ind Meeting With FDA For Phase 2 Study Of Levosimendan

April 4 (Reuters) - Tenax Therapeutics Inc:

* TENAX THERAPEUTICS ANNOUNCES RESULTS OF PRE-IND MEETING WITH FDA FOR PHASE 2 STUDY OF LEVOSIMENDAN IN PH HFPEF PATIENTS

* FDA AGREED THAT NEW PHASE 2 CLINICAL PROTOCOL CAN BE SUBMITTED UNDER EXISTING IND

* HFPEF PATIENTS Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below